Roth Capital Starts Trevena (TRVN) at Buy, $14.50 PT

Roth Capital initiates coverage on Trevena (NASDAQ: TRVN) with a Buy rating and a price target of $14.50.

Analyst Michael Higgins recommends buying ahead of TRV130's Phase 2b 3Q15 results. Higgins highlighted:

• Trevena is developing two new chemical entities: TRV130, an IV analgesic for post-op pain; and TRV027, an IV for acute heart failure (AHF).
• TRV130 – A more effective analgesic in moderate-to-severe post-op patients, with a lower adverse event profile than morphine.
• TRV027 – Compelling early-stage clinical data in AHF, with Actavis holding exclusivity option. Phase 2b data due mid-'16

For an analyst ratings summary and ratings history on Trevena click here. For more ratings news on Trevena click here.

Shares of Trevena closed at $6.93 yesterday.

You May Also Be Interested In

• DA Davidson Starts Everus (ECG) at Buy
• Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
• Viking Holdings (VIK) PT Raised to $82 at Mizuho